When was Elypta founded?

Elypta was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Elypta located?

Elypta is headquartered in Stockholm, Sweden.

How many employees does Elypta have?

As of Aug 31, 2026, the latest employee count at Elypta is 30.

Is Elypta a funded company?

Elypta is a funded company, having raised a total of $27.9M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 04, 2019.

When was the latest funding round of Elypta?

Elypta's latest funding was a $***** Series A round on Jun 20, 2022, with participation from 7 investors. Its primary sector is Genomics. In Sweden, the Genomics sector has seen $23.6M in funding in 2026 to date.

Where does Elypta rank among its competitors?

Elypta ranks 95th amongst 572 active competitors, of which 162 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Elypta?

Elypta's top competitors include Natera, Guardant Health and GRAIL. Among them, GRAIL secured the most recent funding round in June, 2026.

Elypta - 2026 Company Profile, Team, Funding & Competitors

Elypta is a series A company based in Stockholm (Sweden), founded in 2017 by Jens Nielsen and Francesco Gatto. It operates as a Provider of liquid biopsy-based molecular diagnostics for cancer detection. Elypta has raised $27.9M in funding from investors like Industrifonden, Sciety and Bonnier Capital. The company has 572 active competitors, including 162 funded and 116 that have exited. Its top competitors include companies like Natera, Guardant Health and GRAIL.

Company Details

Provider of liquid biopsy-based molecular diagnostics for cancer detection. The company offers a liquid biopsy platform for the detection and monitoring of the disease. The test is based on the measurement of various biomarkers. The test uses machine learning algorithms to generate a score against cancer-type specific signatures. The test is primarily meant for renal cell carcinoma. The test helps in early detection, differential diagnosis, and monitoring or prediction of treatment response, replacing or complementing medical imaging.

Website: elypta.com
Social
Email ID: *****@elypta.com
Phone Number: +46 **********

Key Metrics

Founded Year

2017

Location

Stockholm, Sweden

Stage

Series A

Total Funding

$27.9M in 5 rounds

Latest Funding Round

Series A, Jun 20, 2022, $*****

Investors

Industrifonden & 13 more

Ranked

95^th among 572 active competitors

Employee Count

30 as on Aug 31, 2026

Similar Companies

Natera & 646 more

View Elypta's full profile

Elypta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Elypta Ab CIN: 559112-1214 , Sweden, Active		$0 - $1M (As on Dec 31, 2018)	-	-

Elypta has raised a total funding of $27.9M over 5 rounds. Its first funding round was on Feb 04, 2019. Its latest funding round was a Series A round on Jun 20, 2022 for $*****. 7 investors participated in its latest round. Elypta has 14 institutional investors.

Here is the list of recent funding rounds of Elypta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 20, 2022	9120165	Series A	9510783	1791397	5668824	3156151
May 31, 2022	1555410	Grant (prize money)	5930464	8774697	1908368	EIC Fund
Dec 2019	5160582	Seed	8028193	6483771	Industrifonden & 1 more	Nina Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Elypta's funding rounds and investors

The founders of Elypta are Jens Nielsen and Francesco Gatto.

Here are the details of Elypta's key team members:

Jens Nielsen: Co-Founder & Chairman of Elypta.
Francesco Gatto: Co-Founder & CSO of Elypta.
Contact Info: 1 email address

View details of Elypta's Founder profiles and Board Members

Elypta's employee count trend

Elypta has 30 employees as of Aug 26. Here is Elypta's employee count trend over the years:

Uncover Elypta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elypta include Natera, Guardant Health and GRAIL. Here is the list of Top 10 competitors of Elypta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	80/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
3rd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	78/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
7th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
8th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
9th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
10th	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	66/100
95th	Elypta 2017, Stockholm (Sweden), Series A	Provider of liquid biopsy-based molecular diagnostics for cancer detection	$27.9M	Industrifonden, Bonnier Capital & 12 others	44/100